How to Value a Cardiology Practice in 2026

Cardiology practices are among the most valuable physician practices in the M&A market, and it's not because cardiologists charge high fees. It's because well-run cardiology groups generate substantial ancillary revenue from in-office diagnostics and procedures that most other specialties simply can't replicate. That ancillary revenue stream is what separates a cardiology practice valued at 6x EBITDA from one commanding 12x.

I've been involved in cardiology transactions ranging from two-physician groups selling to hospital systems to 30-provider platforms attracting PE capital, and the valuation dynamics are consistently different from general medical practice sales. Here's what actually drives the numbers.

Why Cardiology Commands Premium Multiples

Cardiology practices typically trade at 6-12x EBITDA, meaningfully above the 4-8x range for most physician specialties. Three factors drive this premium.

Ancillary revenue density. A general internist generates revenue from office visits and maybe a basic lab. A cardiologist generates revenue from office visits plus echocardiography, stress testing, nuclear imaging, Holter monitoring, vascular ultrasound, and in some cases, cardiac catheterization. A single echo machine generating 15-20 studies per week at $400-800 per study adds $300K-$800K in annual revenue with 70%+ margins. Multiply that across modalities, and ancillary services can represent 40-60% of total practice revenue.

Aging demographics.Cardiovascular disease remains the leading cause of death in the United States, and the patient population grows every year as baby boomers age into the highest-utilization cohort. Buyers see a built-in demand tailwind that doesn't exist in many other specialties.

Hospital dependency.Hospitals need cardiologists — they're the highest-admitting specialty and drive enormous downstream revenue in cath labs, cardiac surgery, and inpatient cardiology services. This gives cardiology groups leverage in hospital negotiations and creates multiple buyer pools competing for the same practices.

Ancillary Revenue: The Valuation Multiplier

Let me be direct about this: the ancillary service mix is the single most important factor in cardiology practice valuation. Two practices with identical patient panels and provider counts can have wildly different valuations based on what they've built in-house.

Echocardiography is the baseline. Nearly every cardiology practice has echo capability, and it should represent a meaningful revenue stream. Practices performing 3,000+ echos annually with accredited labs (IAC accreditation) are operating at the standard buyers expect.

Nuclear cardiology is the next tier. A nuclear stress lab requires significant capital ($300K-$600K for a SPECT camera, plus buildout) but generates $500K-$1.5M annually in a busy practice. Practices with nuclear capability are immediately more valuable because the capital barrier keeps competitors out and the reimbursement remains strong relative to other imaging modalities.

Cardiac catheterization is the top tier. Office-based cath labs (OBLs) are the most significant value driver in cardiology right now. A practice performing diagnostic catheterizations and peripheral interventions in its own facility captures the full technical and professional fee — revenue that would otherwise go to the hospital. Cath lab-equipped practices regularly command 10-12x EBITDA because buyers are acquiring a procedural revenue stream with high margins and significant barriers to replication.

The absence of ancillary services is equally telling. A cardiology practice that refers out most diagnostics to hospitals or imaging centers is leaving revenue on the table, and buyers see a practice that hasn't been optimized. That's a 6-7x EBITDA practice, not a 10x practice.

Hospital Co-Management Agreements

One of the most nuanced aspects of cardiology valuation is the role of hospital co-management agreements. These arrangements — where the cardiology group provides medical directorships, quality oversight, or service line management for a hospital's cardiovascular program — generate $200K-$1M+ annually in management fees.

From a valuation perspective, co-management revenue is a double-edged sword. On one hand, it's high-margin, predictable income that demonstrates the practice's strategic importance. On the other hand, these agreements are typically tied to specific physicians and may not survive an ownership change — particularly if the buyer is a competing hospital system.

Sophisticated buyers will value co-management revenue at a discount to clinical revenue, typically applying a 1-2x lower multiple to that income stream. If your practice generates $4M in clinical EBITDA and $500K from a hospital co-management agreement, don't expect the buyer to apply your full multiple to both. They'll likely value the co-management piece separately and conservatively.

Provider Count and Composition

The number and type of providers in your group directly affects both the multiple and the buyer pool.

Solo and two-physician practices face the toughest market. The owner dependency risk is extreme — if the selling cardiologist leaves and takes patient relationships, the buyer is left with expensive equipment and an empty schedule. These practices typically sell at 6-8x EBITDA, often to hospital systems looking to lock in referral patterns and call coverage.

Mid-size groups (4-8 cardiologists)hit the sweet spot for most buyers. They're large enough to survive the departure of any single physician, they have enough volume to justify full ancillary services, and they're small enough that integration isn't overwhelming. These groups trade at 8-10x EBITDA and attract both hospital systems and PE-backed platforms.

Large groups (10+ cardiologists) with multiple locations and subspecialty coverage (interventional, electrophysiology, heart failure, structural heart) are platform-quality assets. Private equity buyers will pay 10-12x EBITDA for these groups because they serve as the foundation for a regional cardiology consolidation strategy.

Provider composition matters too. A group with a balanced mix of clinical cardiologists, interventionalists, and electrophysiologists is more valuable than one dominated by a single subspecialty. Advanced practice providers (NPs and PAs) handling routine follow-ups while physicians focus on procedures is the operating model buyers want to see.

The Buyer Landscape

Cardiology practices attract three distinct buyer types, each with different valuation approaches.

Hospital systemsremain the dominant buyer for small and mid-size groups. They're buying referral patterns, call coverage, and downstream hospital revenue (every dollar of cardiology practice revenue generates an estimated $3-5 in downstream hospital revenue from cath lab procedures, cardiac surgery, and inpatient stays). Hospital buyers apply strategic premiums that financial buyers won't, but they also impose employment models that many physicians find restrictive.

PE-backed cardiology platformshave emerged aggressively since 2020. Companies like US Heart & Vascular, Cardiovascular Associates of America, and several smaller platforms are consolidating independent cardiology groups using the same playbook that worked in dermatology and ophthalmology. They pay competitive multiples (9-12x for platform-quality groups) and let physicians maintain more clinical autonomy than hospital employment.

Other physician groups occasionally acquire smaller practices for geographic expansion or subspecialty addition, but these transactions are less common and typically valued lower (6-8x) because the buyer lacks institutional capital.

What Moves Cardiology Valuations Up or Down

Payer mixis critical. Commercial insurance reimbursement for cardiology services runs 2-4x Medicare rates. A practice with 50%+ commercial payer mix is dramatically more profitable than one that's 70% Medicare. With the Medicare population growing and reimbursement under constant pressure, buyers heavily weight the commercial payer percentage in their models.

Referral base diversification matters. If 40% of your new patients come from three primary care groups, you have a concentration risk that buyers will discount. Practices with broad, diversified referral networks from dozens of PCPs are more resilient and more valuable.

Facility ownership vs lease plays into the deal structure. If your practice owns its office and ancillary facilities, that real estate is typically separated from the practice sale and structured as a long-term lease. This can add significant value to the overall transaction but also introduces complexity.

Physician age and retention risk is the elephant in the room. If three of your five cardiologists are over 60, the buyer is looking at a succession crisis within 5-7 years. Groups with a mix of experienced physicians and younger partners (or employed physicians on track for partnership) present much lower risk and command higher multiples.

The Bottom Line

Cardiology practice valuation at 6-12x EBITDA reflects the specialty's unique combination of high ancillary revenue potential, favorable demographics, and strategic importance to hospital systems. The practices commanding top-of-market multiples are those that have built robust in-office diagnostic and procedural capabilities, assembled multi-provider groups with subspecialty depth, and maintained diversified payer mixes with strong commercial insurance penetration.

If you're running a cardiology practice and thinking about an eventual transaction, the highest-ROI moves are investing in ancillary services you don't yet offer, recruiting younger physicians to reduce key-person risk, and building your commercial payer panel. Those three actions can move you from the 6-8x range to 10x+ over a 2-3 year preparation period.